Pharmaceutical translation demands absolute precision, as even the smallest error can impact patient safety or regulatory approval. Pharmaceutical translation companies specialize in converting medical research, clinical trial data, and regulatory filings into multiple languages while meeting strict compliance standards.
Common questions about pharmaceutical translation answered by our team.
Pharmaceutical translation is the highly specialized conversion of drug development, clinical research, regulatory submission, and product documentation for use in international markets. It requires translators with advanced scientific qualifications and deep familiarity with FDA, EMA, and ICH regulatory frameworks. A single mistranslated term in a drug label or clinical trial protocol can have serious patient safety and regulatory consequences. Translation Ratings lists 7 pharmaceutical translation specialists in the United States.
Common pharmaceutical translation projects include: investigational new drug (IND) applications, new drug applications (NDA) and abbreviated NDAs (ANDA), marketing authorization applications (MAA) for the EMA, clinical trial protocols and amendments, clinical study reports (CSRs), investigator brochures (IB), informed consent forms (ICFs), drug package inserts and patient information leaflets, pharmacovigilance reports, product labeling and packaging, and regulatory correspondence.
Pharmaceutical translation must comply with: FDA regulations under 21 CFR (particularly Parts 312, 314, 600), EMA requirements for centralized marketing authorization, ICH guidelines (E6 for GCP, E3 for clinical study reports, M4 for CTD format), EU Falsified Medicines Directive requirements for package leaflet translations, and ISO 17100 for translation service quality. Submissions with non-compliant translations risk rejection by health authorities.
Back-translation involves translating a document from the target language back into the source language (typically English) by an independent translator who has not seen the original, to check for errors or deviations in meaning. It is commonly required by regulatory authorities and ethics committees for translated informed consent forms, patient questionnaires (PROs), and clinical assessment instruments. ICH E6 GCP guidelines recommend this practice for patient-facing clinical trial documents.
The Common Technical Document (CTD) is the internationally agreed format for pharmaceutical regulatory submissions, organized in five modules. When submitting to health authorities in non-English-speaking countries, the clinical and safety modules may require translation into the local language. Some authorities accept English for scientific modules but require local language translations for labeling, patient information, and summaries. Experienced pharmaceutical translation agencies are familiar with CTD structure and can manage multi-language regulatory packages.
Pharmaceutical translators must hold advanced degrees (PhD or MSc) in pharmacology, chemistry, medicine, biochemistry, or closely related disciplines. Direct experience working in the pharmaceutical industry, a CRO, or regulatory affairs is highly valued. Knowledge of GxP principles (GMP, GCP, GLP), ICH guidelines, drug nomenclature (INN, USAN), and pharmacokinetic and pharmacodynamic terminology is essential.
Pharmaceutical translation is the most expensive category in the professional translation market due to the required expertise and regulatory risk. Rates range from $0.25 to $0.60 per source word for common language pairs. A full clinical study report of 150 pages (approximately 45,000 words) might cost $11,250 to $27,000. Complete NDA or MAA packages spanning hundreds of documents across multiple languages can represent translation investments of $200,000 or more.